OncoMatch/Clinical Trials/NCT07410975
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
Is NCT07410975 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies sintilimab+IBI310+chemotherapy for nsclc stage ii.
Treatment: sintilimab+IBI310+chemotherapy — This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in patients with PD-L1-negative stage II - IIIB (excluding N3) NSCLC (according to AJCC 9th) scheduled for surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
no EGFR mutation
Required: ALK wild-type
no ALK rearrangement
Required: PD-L1 (CD274) expression negative (22C3 or E1L3N) (negative)
PD-L1 expression negative (22C3 or E1L3N)
Disease stage
Required: Stage II, IIIA, IIIB (AJCC 9th)
Investigator-assessed resectable Stage II-IIIB (N3 excluded) NSCLC per AJCC 9th
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy
Cannot have received: immunotherapy
No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy
Cannot have received: radiotherapy
No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy
Lab requirements
Blood counts
haemoglobin ≥ 90 g/l (no transfusion within 28 days); absolute neutrophil count ≥ 1.5 × 10⁹/l; platelet count ≥ 100 × 10⁹/l (no platelet transfusion or il-11 within 14 days)
Kidney function
creatinine clearance ≥ 60 ml/min (cockcroft-gault)
Liver function
total bilirubin ≤ 1.5 × uln (≤ 2.5 × uln in gilbert's syndrome or hepatic metastases); alt and ast ≤ 3 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07410975 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression negative (22C3 or E1L3N) is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages